Sana Biotechnology Appoints Brian Piper as CFO and Executive Vice President

Sana Biotechnology, Inc. (NASDAQ: SANA) announced on February 17, 2026, the appointment of Brian Piper as Executive Vice President and Chief Financial Officer. The appointment ended the interim role of CEO Steve Harr as acting principal financial officer. Piper also received the titles of Treasurer and Principal Financial Officer.

Piper brings to Sana a breadth of biopharmaceutical financial and operational expertise with over 25 years of experience in various positions in the industry. He was most recently CFO of Scorpion Therapeutics and its post-acquisition spin-off, Antares Therapeutics. Piper was previously Chief Financial Officer of Scorpion Therapeutics until its acquisition by Eli Lilly in 2025, and thereafter was Chief Financial Officer of Antares Therapeutics, following its spin-off from Scorpion. Prior to that, he was Chief Financial Officer of Prelude Therapeutics, a public biotech company. Earlier, he served as Chief Financial Officer of Aevi Genomic Medicine.

He also spent 13 years at Shire Pharmaceuticals, holding senior roles across investor relations, corporate venture capital, and other finance functions. Piper began his career at Celera Genomics and Otsuka Pharmaceuticals, Inc. He obtained his M.B.A. from the University of Maryland and his B.B.A. from the University of Notre Dame.

The President and Chief Executive Officer stated he brings deep expertise in capital formation and disciplined capital allocation along with a proven track record of driving financial and operational excellence. Over the next 12-18 months, the company expects to generate initial clinical data for SC451 in the treatment of type 1 diabetes and SG293 in a B-cell related disease, helping better understand these therapies and creating important value inflection points for the company. The company has meaningful momentum in its type 1 diabetes and in vivo CAR T programs, and his leadership will be critical as the company continues to advance its portfolio, optimize long‑term value creation, and work to deliver these transformative therapies for patients.

Commenting on his appointment, Piper stated he is delighted to join the Sana team at a pivotal time as the company builds on the demonstrated clinical potential of hypoimmune-modified pancreatic islet cells in type 1 diabetes and starts clinical development for the in vivo CAR T platform. He looks forward to working closely with the team to ensure a strong balance sheet, drive operational excellence, and apply disciplined capital allocation in support of the company's vision for patient impact and shareholder value.

Under the terms of his offer, Piper will receive a $515,000 base salary, a target annual bonus equal to 40% of salary, and equity awards comprising stock options for 900,000 shares and 200,000 restricted stock units that vest over four years. His compensation package includes severance protections and eligibility under Sana's change-in-control severance plan.

Sana Biotechnology is a company focused on creating and delivering engineered cells as medicines for patients. The company went public in 2021 and has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA. In pre-market hours following the announcement, SANA was trading at $3.85 on the Nasdaq.